Influence of GLP1R and TCF7L2 genetic variants on type 2 diabetes remission following Roux-en-Y gastric bypass.

BACKGROUND

Obesity is the primary risk factor for type 2 diabetes mellitus (T2DM), characterized by progressive loss of pancreatic function. Genetic variants in key genes, such as GLP1R and TCF7L2, play a crucial role in glycemic control, and dysfunctions may impair insulin secretion by pancreatic β-cells.

OBJECTIVES

To evaluate the influence of GLP1R and TCF7L2 genetic polymorphisms on T2DM remission in patients undergoing Roux-en-Y gastric bypass (RYGB).

SETTING

University Hospital, Brazil.

METHODS

This study was approved by the ethics committee (no. 6.158.558) and included 70 patients who underwent RYGB. Blood samples were collected for laboratory and genetic analyses. Genomic DNA was extracted and analyzed via real-time polymerase chain reaction (PCR) using TaqMan probes. Statistical analyses were performed using SPSS 29.0, including Student t test, Spearman correlation, Fisher exact test, and χ2 test (P ≤ .05).

RESULTS

The GLP1R rs10305420 polymorphism was associated with decreased proportional weight loss over time and increased glycated hemoglobin (HbA1C) (%) after surgery (P = .04). The TCF7L2 rs7903146 polymorphism was associated with increased postoperative HbA1C (P = .036).

CONCLUSIONS

The GLP1R rs10305420 variant reduces weight loss and increases HbA1C (%) after RYGB. The TCF7L2 rs7903146 variant also increases HbA1C (%) and reduces T2DM remission following RYGB.